KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 78 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $999,536 | +12.0% | 103,794 | +4.7% | 0.00% | +50.0% |
| Q2 2023 | $892,458 | +108.9% | 99,162 | +82.4% | 0.00% | +100.0% |
| Q1 2023 | $427,309 | +263.0% | 54,365 | +212.2% | 0.00% | – |
| Q4 2022 | $117,732 | -68.1% | 17,416 | -53.5% | 0.00% | -100.0% |
| Q2 2022 | $369,000 | -71.4% | 37,453 | -61.6% | 0.00% | -66.7% |
| Q4 2021 | $1,291,000 | -39.7% | 97,592 | -20.4% | 0.00% | -40.0% |
| Q3 2021 | $2,140,000 | +57.0% | 122,643 | +115.6% | 0.01% | +66.7% |
| Q2 2021 | $1,363,000 | -34.2% | 56,878 | -29.5% | 0.00% | -40.0% |
| Q1 2021 | $2,072,000 | +284.4% | 80,673 | +184.1% | 0.01% | +150.0% |
| Q4 2020 | $539,000 | +63.3% | 28,396 | +4.2% | 0.00% | 0.0% |
| Q2 2020 | $330,000 | +8.9% | 27,262 | +99.1% | 0.00% | +100.0% |
| Q2 2019 | $303,000 | +7.4% | 13,696 | +7.5% | 0.00% | 0.0% |
| Q3 2018 | $282,000 | – | 12,740 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 422,310 | $10,849,000 | 5.86% |
| COMMODORE CAPITAL LP | 214,467 | $5,510,000 | 2.20% |
| Vivo Capital, LLC | 1,863,296 | $47,868,000 | 1.68% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 214,533 | $5,486,000 | 1.45% |
| Nicholas Investment Partners, LP | 594,130 | $15,263,000 | 1.06% |
| Altium Capital Management LP | 128,130 | $3,292,000 | 0.91% |
| Affinity Asset Advisors, LLC | 100,000 | $2,569,000 | 0.87% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,000 | $1,285,000 | 0.70% |
| APIS CAPITAL ADVISORS, LLC | 30,000 | $771,000 | 0.70% |
| Birchview Capital, LP | 40,000 | $1,028,000 | 0.61% |